Market Data 
Markets
Replies to post #78650 on Biotech Values
Among larger, more established biotech players, Markowitz likes Celgene. The company's stock is off 28% this year as sales of its already approved drugs have proved less resistant to recession than expected. Earnings will still grow 25% this year, and a new treatment for hepatitis C could be a winner, even though new offerings from competitors Vertex Pharmaceuticals and Schering-Plough may beat Celgene to market, he says.
AI
